Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Psoriasis Biomarkers: Exploring Precision Medicine for Improved Patient Care

Description

The discussion centers on the emerging field of psoriasis biomarkers and the role of precision medicine in improving patient care. Biomarkers, as defined by the NIH, are objective indicators of biological processes that can aid in tailoring personalized treatments for psoriasis patients. The focus is on developing tests that can predict disease severity, potential progression to psoriatic arthritis, and the best therapeutic options based on individual patient data, including blood and tissue samples. Current research efforts are extensive, with hundreds of candidate biomarkers identified. Key areas of investigation include identifying genetic, proteomic, and metabolic markers that can guide treatment decisions for various therapies, including TNF blockers and IL-17 inhibitors. Notably, a new FDA-approved device from the company Mindira aims to analyze RNA from psoriatic patients to predict treatment responses, reflecting advancements in the clinical application of biomarkers. Although no standardized biomarkers are currently validated for clinical use, the development of these tools represents a significant step toward personalized medicine in dermatology.

View more

Conclusions

Biomarkers have the potential to significantly enhance the precision medicine approach in psoriasis treatment.
The integration of biomarkers could personalize treatment plans based on individual patient data, potentially improving patient outcomes.
Current research is focusing on identifying biomarkers that predict disease severity and the likelihood of developing psoriatic arthritis.
Candidate biomarkers currently being studied include genomic, proteomic, and metabolic markers associated with psoriasis.
There is ongoing research aimed at determining the best therapeutic options for patients based on biomarker analysis.
High-throughput technologies like RNA extraction devices may facilitate more accurate predictions of treatment responses in psoriasis patients.
Despite the promising advancements, no validated biomarkers are currently available for routine clinical use in psoriasis treatment.
The future of biomarker integration in psoriasis treatment is optimistic, with new technologies enhancing predictive analytics capabilities.

Biomarkers Definition Working Group Biomarkers and surrogate endpoints, Clin Pharmacol Therapeutics, 2001
Yiu et al, J Invest Dermatol, 2021
Chris Griffiths, University of Manchester, 2023
Ramessur et al, Br J Dermatol, 2022
Corbett et al, Br J Dermatol, 2022
Dand et al, J Allergy Clin Immunol, 2019
Munoz-Aceituno et al, J Eur Acad Dermatol Venereol, 2024
Liu et al, Clin Transl Med, 2024
minderahealth.com